简明综述：心脏细胞疗法是否已死？令人尴尬的试验结果与未来的新方向。
Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future.
机构信息
Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
出版信息
Stem Cells Transl Med. 2018 Apr;7(4):354-359. doi: 10.1002/sctm.17-0196. Epub 2018 Feb 22.
Stem cell therapy is a promising strategy for tissue regeneration. The therapeutic benefits of cell therapy are mediated by both direct and indirect mechanisms. However, the application of stem cell therapy in the clinic is hampered by several limitations. This concise review provides a brief introduction into stem cell therapies for ischemic heart disease. It summarizes cell-based and cell-free paradigms, their limitations, and the benefits of using them to target disease. Stem Cells Translational Medicine 2018;7:354-359.
干细胞疗法是组织再生的一种有前途的策略。细胞疗法的治疗益处通过直接和间接机制介导。然而，干细胞疗法在临床上的应用受到多种限制。本简明综述简要介绍了用于缺血性心脏病的干细胞疗法。它总结了基于细胞和无细胞的范例、它们的局限性以及利用它们来靶向疾病的好处。《干细胞转化医学》2018；7：354-359。
Zotero 插件